This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Essential cookies enable basic functions and are necessary for the website to function properly.
Statistics cookies collect information anonymously. This information helps us to understand how our visitors use our website.
Marketing cookies are used by third parties or publishers to display personalized advertisements. They do this by tracking visitors across websites.

ITM-31 for Glioblastoma

Therapeutic ITM-31 (n.c.a. 177Lu-TTM*)

Glioblastoma is one of the most malignant types of primary brain tumors. It is a rare tumor, with about 3 new cases per 100,000 individuals per year with a poor prognosis.1 Even though surgery, chemotherapy, and radiotherapy have advanced over the last decade, resulting in a gradual improvement in the survival and quality of life of glioblastoma patients, the prognosis remains depressing.2

Glioblastoma is a complex tumor which is very difficult to treat. Surgery is rarely curative as the tumor cells infiltrate the surrounding tissue and the blood-brain barrier places a limitation on medical therapies.

In conjunction with a scientific partner, ITM is developing ITM-31, a novel n.c.a. 177Lu-TTM*, for intra-cavitary immunoradiotherapy (iRIT) in patients suffering from glioblastoma. ITM-31 consists of two molecular components – firstly, n.c.a. Lutetium-177 (EndolucinBeta®), a synthetic, low-energy beta-emitting isotope of Lutetium, and secondly, a nondisclosed tumor-targeting molecule TTM*, specifically targeting glioblastoma cells.


*TTM = Tumor-Targeting Molecule; nondisclosed

1 Gallego, 2015, Current Oncology 22(4): e273–e281 and
  Bahadur et al., 2019, Oncology Reviews 13(2): 417
2 Gallego, 2015, Current Oncology 22(4): e273–e281 and
  Weller et al., 2013, Neuro-Oncology 15(1): 4–27

Please note: ITM-31 (n.c.a. 177Lu-TTM) is not authorized for marketing in any country at this time.